Barclays
GMVD

Barclays’s G Medical Innovations Holdings Ltd. Ordinary Shares GMVD Stock Holding History

Barclays’s Portfolio GMVD Stock Details GMVD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-56,001
Closed -$51K – 5265
2023
Q1 		$51K Buy
+56,001
New +$161K ﹤0.01% 4438

Other funds holding GMVD

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
HWM
HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Barclays's GMVD Position: Q2 2023 in Review

Barclays sold out of G Medical Innovations Holdings Ltd. Ordinary Shares (GMVD) in Q2 2023, closing a stake of 56,001 shares — an estimated $51K sold.

Barclays first reported a position in GMVD in Q1 2023 and held it in 1 quarter. The position peaked at $51K in Q1 2023. 8 funds tracked by Wall St. Rank hold GMVD as of Q2 2023.

  • Barclays reported no remaining G Medical Innovations Holdings Ltd. Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Barclays sold 56,001 G Medical Innovations Holdings Ltd. Ordinary Shares shares in Q2 2023, an estimated $51K.
  • Barclays first reported a position in G Medical Innovations Holdings Ltd. Ordinary Shares in Q1 2023 and held it in 1 quarter.
  • Barclays's G Medical Innovations Holdings Ltd. Ordinary Shares position peaked at $51K in Q1 2023.
  • 8 funds tracked by Wall St. Rank held G Medical Innovations Holdings Ltd. Ordinary Shares as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.